New England Journal of Medicine Publishes Phase 1/2 Data on Revolution Medicines' Daraxonrasib for NSCLC

Revolution Medicines has published early clinical trial results for its experimental drug daraxonrasib (RASONQUE) targeting metastatic non-small cell lung cancer, marking a significant step in evaluating its safety and efficacy profile.